A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
- Status
- TERMINATED
- Phase
- PHASE3
CADY Study ICORG 08-01
- Status
- COMPLETED
- Phase
- N/A
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab in Treating Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA